Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.
Edward Azavedo, Jonas Bergh, Yvonne Brandberg, Johan Hartman, Ioannis Zerdes, Claudia Maes, Hemming Johansson, Mats Hellström, Per Grybäck, Susanne Agartz, Erika Isaksson-Friman, Ann Charlotte Dreifaldt, Lena Carlsson, Anne Andersson, Jamila Adra, Zakaria Einbeigi, Aglaia Schiza, Henrik Lindman, Gyula Pekar, Ana Bosch, Ellinor Elinder, Hanna Fredholm, Tobias Lekberg, Judith Bjöhle, Theodoros Foukakis, Thomas Hatschek
JAMA oncology 2022;7(9):1360-1367